Amgen announced full results from Part 1 of the Phase II study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type… read more.
Clearside Biomedical, Inc, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that the use of its… read more.
BMS announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase II, single-arm study… read more.
Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study… read more.
Connect Biopharma Holdings Limited (a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations… read more.
Tonix Pharmaceuticals Holding Corp. announced a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, being held June 11-14, 2025, in Barcelona, Spain. Details on the… read more.
Sobi will have a strong scientific presence at this year’s ERA congress in Vienna (4-7 June) with a total of eight presentations: six oral presentations and two posters…. read more.
Sobi will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 June 2025. Research will include… read more.
Eli Lilly and Company announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at the American… read more.
Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO)… read more.
Bristol Myers Squibb announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held… read more.
Eli Lilly and Company announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
